Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance
Kevin Holm, Neil A. Bhowmick
Kevin Holm, Neil A. Bhowmick
View: Text | PDF
Commentary

Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance

  • Text
  • PDF
Abstract

Advanced prostate cancer frequently escapes androgen receptor pathway inhibition through mechanisms including restored androgen signaling, lineage plasticity, and metabolic adaptation. Neuroendocrine prostate cancer (NEPC) can emerge as an androgen-insensitive lineage and has mostly been studied in the context of its transcriptional and epigenetic reprogramming. However, evidence increasingly supports the requirement for metabolic rewiring across a variety of pathways in the transition to NEPC. In this issue of the JCI, Wei et al. demonstrated that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) stabilizes the plastic state of NEPC by supporting serotonin-based posttranslational modification (serotonylation) of mTOR and FOXM1/E2F1 activation. These findings position TPH1 as both a neuroendocrine marker and a functional mediator of hormone therapy resistance. Because metabolic escape can involve many pathways, biomarker-guided patient selection will be required for translating these findings to an intervention. Accordingly, targeting TPH1 may delay or reverse therapy-induced NEPC in selected patients.

Authors

Kevin Holm, Neil A. Bhowmick

×

Figure 1

Drivers of hormone therapy escape.

Options: View larger image (or click on image) Download as PowerPoint
Drivers of hormone therapy escape.
Prostate adenocarcinoma under androge...
Prostate adenocarcinoma under androgen receptor (AR) pathway inhibition induces multiple treatment-resistant states. The heterogenous resulting tumor cells can develop resistance through AR signaling restoration, bypassing AR signaling through glucocorticoid receptor activation, metabolic rewiring, and transformation of the paracrine signaling axis. Wei et al. (18) connected serotonin metabolism to neuroendocrine subtypes of treatment resistance, showing that tryptophan hydroxylase 1 (TPH1) upregulation in models of neuroendocrine prostate cancer (NEPC) increased tryptophan conversion to serotonin, supporting serotonylation of targets such as mTOR that contribute to a neuroendocrine differentiation state.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts